Evaluation of the efficacy and safety of Melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial

AbstractObjectivesWe will evaluate the efficacy and safety of Melatonin, compared to the standard therapeutic regimen on clinical symptoms and serum inflammatory parameters in patients with confirmed COVID-19, who are moderately ill.Trial designThis is a single-center, randomized, double-blind, placebo-controlled clinical trial with a parallel-group design conducted at Shahid Mohammadi Hospital, Bandar Abbas, Iran.ParticipantsAll patients admitted to Severe Acute Respiratory Syndrome Departments of Shahid Mohammadi Hospital, Bandar Abbas, Iran will be screened for the following criteria.Inclusion criteria:1. Age ≥20 years2. Confirmed SARS-CoV-2 diagnosis (positive polymerase chain reaction).3. Moderate COVID-19 pneumonia (via computed tomography and or X-ray imaging), requiring hospitalization.4. Hospitalized ≤48 hours.5. Signing informed consent and willingness of the participant to accept randomization to any assigned treatment arm.Exclusion criteria:1. Underlying diseases, including chronic hypertension, diabetes mellitus, seizure, depression, chronic hepatitis, cirrhosis, and cholestatic liver diseases.2. Severe and critical COVID-19 pneumonia.3. Use of warfarin, corticosteroids, hormonal drugs, alcohol, other antiviral and investigational medicines, and illegal drugs (during the last 30 days).4. History of known allergy to Melatonin.5. Pregnancy and breastfeeding.Intervention and comparatorIntervention group: The standard treatment regimen for COVID-19, according to ...
Source: Trials - Category: Research Source Type: clinical trials